Sugi Predict

Sugi Predict / Compounds / SCHEMBL256771

SCHEMBL256771

SCHEMBL256771

COCc1cc(C(=O)OC)ccc1Br

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 1/20 0.50
▸ CA1 P00915 4/20 0.47
▸ CA2 P00918 4/20 0.47
▸ CA12 O43570 3/20 0.47
▸ CA7 P43166 3/20 0.47
▸ CA9 Q16790 3/20 0.47
▸ CA14 Q9ULX7 3/20 0.47
▸ XDH P47989 1/20 0.47
▸ HKDC1 Q2TB90 2/20 0.47
▸ CCR6 P51684 1/20 0.47
▸ PTGDR2 Q9Y5Y4 1/20 0.46
▸ MAPT P10636 5/20 0.44
▸ HPGD P15428 4/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ HSD17B10 Q99714 3/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ GLA P06280 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ CASP1 P29466 1/20 0.44
▸ CASP7 P55210 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30622268 1.00 NOTUM (0.50) NOTUMCA1CA2CA12CA7
SCHEMBL31721787 0.89 P4HB (0.44) NOTUMCA1CA2CA12CA7
SCHEMBL3180951 0.87 MAPT (0.48) NOTUMCA1CA2CA12CA7
SCHEMBL31063216 0.87 NOTUM (0.54) NOTUMCA1CA2CA12CA7
SCHEMBL2358109 0.86 NOTUM (0.53) NOTUMCA1CA2CA12CA7
SCHEMBL3183891 0.86 CA12 (0.51) CA1CA2CA12CA7CA9
SCHEMBL409154 0.86 NOTUM (0.47) NOTUMCA1CA2CA12CA7
SCHEMBL24595665 0.85 ALDH1A1 (0.48) MAPTHPGDALDH1A1GAAMEN1
SCHEMBL256770 0.85 NOTUM (0.51) NOTUMCA1CA2CA12CA7
SCHEMBL408849 0.85 CA1 (0.44) CA1CA2CA12CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025228892-A1 MONOARYL AND HETARYL SUBSTITUTED INDAZOLES AND BENZIMIDAZOLES AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-11-06 — — WO disclosed
US-20250333398-A1 MONOARYL AND HETARYL SUBSTITUTED INDAZOLES AND BENZIMIDAZOLES AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT BOEHRINGER INGELHEIM INT (DE) 2025-10-30 — — US disclosed
WO-2024101440-A1 COMPOUND, ENDOTHELIN A RECEPTOR ANTAGONIST, ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION 株式会社アークメディスン 2024-05-16 — — WO disclosed
CN-117088884-A Imidazopyridazine derivatives as GABAA receptor modulators, pharmaceutical compositions and uses 上海赛默罗德生物科技有限公司 2023-11-21 — — CN disclosed
CN-117069724-A Fused ring compounds, pharmaceutical compositions and uses 上海赛默罗德生物科技有限公司 2023-11-17 — — CN disclosed
WO-2023085415-A1 COMPOUND, ANGIOTENSIN-II TYPE 1 RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION 株式会社アークメディスン 2023-05-19 — — WO disclosed
WO-2023085415-A1 COMPOUND, ANGIOTENSIN-II TYPE 1 RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION 株式会社アークメディスン 2023-05-19 — — WO disclosed
CN-115745983-A Angiotensin and endothelin receptor antagonist and application thereof 深圳信立泰药业股份有限公司 2023-03-07 — — CN disclosed
EP-2414341-B1 OXADIAZOLE DERIVATIVES MERCK SERONO SA (CH) 2017-09-13 — — EP disclosed
EP-2414342-B1 OXADIAZOLE DERIVATIVES MERCK SERONO SA (CH) 2017-05-31 — — EP disclosed
WO-2010115751-A2 OXADIAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2010-10-14 — — WO disclosed
WO-2010112461-A1 OXADIAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2010-10-07 — — WO disclosed
US-20100240658-A1 Oxadiazole Derivatives MERCK SERONO SA (CH) 2010-09-23 — — US disclosed
WO-2010100142-A1 OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS MERCK SERONO S.A. (CH) 2010-09-10 — — WO disclosed
WO-2010100142-A1 OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS MERCK SERONO S.A. (CH) 2010-09-10 — — WO disclosed
EP-2212317-A1 4,4-DISUBSTITUTED PIPERIDINES Novartis AG (CH) 2010-08-04 — — EP disclosed
WO-2010069949-A1 OXADIAZOLE FUSED HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS MERCK SERONO S.A. (CH) 2010-06-24 — — WO disclosed
EP-2193125-A2 OXADIAZOLE DERIVATIVES Merck Serono S.A. (CH) 2010-06-09 — — EP disclosed
WO-2009053452-A1 4,4-DISUBSTITUTED PIPERIDINES NOVARTIS AG (CH) 2009-04-30 — — WO disclosed
WO-2009043889-A2 OXADIAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2009-04-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250333398-A1 MONOARYL AND HETARYL SUBSTITUTED INDAZOLES AND BENZIMIDAZOLES AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT STING1, MAVS, TBK1 NOTUM 2586/4885CA1 4884/4885CA2 3988/4885
US-20100240658-A1 Oxadiazole Derivatives OXA1L, RO60, NQO2 NOTUM 4630/4885CA1 2829/4885CA2 2987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.